NASDAQ:GBT
Delisted
GLOBAL BLOOD THERAPEUTICS Stock News
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Moderna (MRNA) Received its Third Buy in a Row
03:38pm, Wednesday, 15'th Apr 2020
After Piper Sandler and Chardan Capital gave Moderna (NASDAQ: MRNA) a Buy rating last month, the company received another Buy,
Morgan Stanley Sticks to Its Hold Rating for Biohaven Pharmaceutical Holding Co (BHVN)
03:37pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Biohaven Pharmaceutical Holding Co (BHVN) today and set a price target of $46.00. The
Morgan Stanley Sticks to Its Hold Rating for Biohaven Pharmaceutical Holding Co (BHVN)
03:37pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst
Matthew Harrison
maintained a
Hold
rating on Biohaven Pharmaceutical Holding Co (
BHVN
–
Research Report
) today and set a price target of
$46.00
. The company’s shares clos
Morgan Stanley Maintains a Hold Rating on Bluebird Bio (BLUE)
03:35pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Bluebird Bio (BLUE), with a price target of $69.00. The
Morgan Stanley Reaffirms Their Hold Rating on Global Blood Therapeutics (GBT)
03:35pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Global Blood Therapeutics (GBT), with a price target of
Morgan Stanley Reaffirms Their Hold Rating on Global Blood Therapeutics (GBT)
03:35pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Hold
rating on Global Blood Therapeutics (
GBT
–
Research Report
), with a price target of
$70.00
. The company’s shar
Kodiak Sciences (KOD) Received its Third Buy in a Row
03:34pm, Wednesday, 15'th Apr 2020
After J.P. Morgan and BMO Capital gave Kodiak Sciences (NASDAQ: KOD) a Buy rating last month, the company received another Buy, this time from Morgan
Morgan Stanley Maintains Their Hold Rating on Seattle Genetics (SGEN)
03:29pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Seattle Genetics (SGEN) today and set a price target of $111.00. The company's shares
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Morgan Stanley
03:27pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Sarepta Therapeutics (SRPT), with a price target of $172.00.
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Morgan Stanley
03:27pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Sarepta Therapeutics (
SRPT
–
Research Report
), with a price target of
$172.00
. The company’s shares c
BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley
03:27pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on BeiGene (BGNE), with a price target of $184.00. The company's
Galapagos (GLPG) Receives a Hold from Morgan Stanley
03:26pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Galapagos (GLPG) today and set a price target of $226.00. The company's shares closed
Morgan Stanley Believes Vertex Pharmaceuticals (VRTX) Won't Stop Here
03:26pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Vertex Pharmaceuticals (VRTX), with a price target of $258.00.
Morgan Stanley Believes Vertex Pharmaceuticals (NASDAQ: VRTX) Won’t Stop Here
03:26pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Vertex Pharmaceuticals (
VRTX
–
Research Report
), with a price target of
$258.00
. The company’s shares
Morgan Stanley Remains a Hold on Regeneron (REGN)
03:26pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Regeneron (REGN) today and set a price target of $409.00. The company's shares closed
